肠道菌群与糖尿病微血管病变的研究进展  

Overview of the relationship between intestinal flora and diabetic microvascular diseases

作　　者：李欣[1] 寇少杰 李粉萍 薛敬东 陈果[3] 马喜桃[4] 丁蕊 赵小艳 赵雯雯 岳仁宋[1] LI Xin;KOU Shaojie;LI Fenping(Department of Endocrinology,Affiliated Hospital of Chengdu University of TCM,Chengdu 610075,China)

机构地区：[1]成都中医药大学附属医院内分泌科,610075 [2]陕西省中医医院肝病科 [3]成都中医药大学附属医院感染科 [4]成都中医药大学附属医院伦理办 [5]西部战区总医院中医科

出　　处：《中国糖尿病杂志》2023年第4期303-308,共6页Chinese Journal of Diabetes

基　　金：国家自然科学基金(81774279);2018年国家中医药管理局区域中医(肝病)诊疗中心培育单位建设项目[NO.(2017).39];四川省中医药管理局科学技术研究专项(2021MS041);四川省科学技术厅重点研发项目(2021YFS0037);陕西省感染性疾病临床医学研究中心(中西医结合)建设项目(2020LCZX-02)。

摘　　要：DM微血管病变在高血糖刺激下损伤微动静脉和毛细血管,累及肾脏、视网膜、神经等,影响患者生活质量与预期寿命。肠道菌群影响机体物质代谢、能量吸收等,参与DM微血管病变。补充微生态制剂益生菌可能调整肠道菌群结构,影响DM微血管病变进展。本文综述肠道菌群与DM微血管病变的研究进展。Diabetes mellitus(DM)microvascular diseases isa group of common complications that affect the quality of life and life expectancy of patientsby damaging arterioles and capillaries under the stimulation of hyperglycemia,involving kidneys,retina,nerves,etc. Intestinal flora affects the metabolism and energy absorption of the body,and participates in the occurrence of DM microvascular diseases. Supplementing probiotics can improve the intestinal microecology,and then affect the progression of DM and its microvascular disease. This article reviews the research progress of intestinal microflora and diabetic microangiopathy.

关 键 词：肠道菌群 糖尿病 微血管病变 益生菌 

分 类 号：R587.2[医药卫生—内分泌]